Credits Available: 5.0 AMA PRA Category 1 Credits

Description: The proposed activities will inform clinicians of recent evidence from clinical trials on the efficacy and safety of TROP2-directed antibody-drug conjugates (ADCs) in patients with progressive NSCLC, allowing them to quickly integrate new treatments into their practice when they become available. Clinicians will be updated on HER2 genomic alterations and apply appropriate testing methodologies per the National Comprehensive Cancer Network (NCCN) guidelines for NSCLC. Furthermore, participants will receive education on the successful management of NSCLC, including managing brain metastases, optimal HER2-targeted ADC dosing, and monitoring approaches for treatment-related adverse events (AEs). Finally, the proposed activities aim to educate participants on the importance of targeting HER3 and using HER3-directed ADCs in the management of NSCLC. The initiative will also provide information on the efficacy and safety of these ADCs based on clinical trial data, as well as strategies for recognizing and minimizing treatment-related AEs to enhance therapy adherence and improve patient outcomes.

CME/CE Accreditation Information

If you already have a Gather-ed account, please login

Email:
Password:

Register

Step 1 of 3

This program is intended for:
Target Professions: DO, MD, Nurse Practitioner, Physician Assistant
Target Specialties: Oncology

Melvin Rivera

MD Anderson Cancer Center
Clinical Pharmacy Specialist - Thoracic, Head and Neck Medical Oncology

Clinical Pharmacy Specialist in the area of Thoracic, Head and Neck Medical Oncology (THNMO) at MD Anderson Cancer center for the last 16 years. I have worked in both the inpatient and outpatient setting and work alongside medical oncologist and APP's to provide safe and effective oncologic care to THNMO patients. I graduated from Northeastern University Bouve College of Health Sciences in 2005 and completed a PGY-1 and PGY-2 (Oncology) residencies at Boston Medical Center in Boston, MA 2007.